Ascorbic acid supplement during luteal phase in IVF.
OBJECTIVE
To evaluate the impact of ascorbic acid of different doses as additional support during luteal phase in infertility treatment by means of a prospective, randomized, placebo-controlled, group comparative, double-blind study.


METHODS
Voluntary daily oral intake of either ascorbic acid (1, 5, or 10 g/day) or Placebo for 14 days after follicle aspiration for IVF-ET procedure. Data was obtained on 620 cases of women, age <40 years, undergoing first IVF-embryo transfer cycles in two private outpatient infertility clinics. All women were stimulated by the same protocol. The mean age was 31.73 (+/- 4.4 SD) years.


RESULTS
No differences in clinical pregnancy rate and implantation rate were noted in statistical logistic regression analysis between the four intake groups.


CONCLUSIONS
There was no clinical evidence of any beneficial effect, as defined by main outcome measures, of ascorbic acid on IVF-ET. Our data suggest there is no obvious value of high dosed intake of vitamin C during luteal phase in infertility treatment.
Griesinger
Georg
G
Department of Obstetrics and Gynecology, University of Vienna, Waehringer Guertel, Austria.
Franke
Katharina
K
Kinast
Cordelia
C
Kutzelnigg
Alexandra
A
Riedinger
Sandra
S
Kulin
Sandor
S
Kaali
Steven G
SG
Feichtinger
Wilfried
W
D000328:Adult; D000367:Age Factors; D001205:Ascorbic Acid / Q000008:administration & dosage* / Q000378:metabolism; D004311:Double-Blind Method; D004624:Embryo Transfer; D005260:Female; D005307:Fertilization in Vitro; D006801:Humans; D007246:Infertility / Q000628:therapy; D016014:Linear Models; D008183:Luteal Phase; D008297:Male; D011247:Pregnancy; D011446:Prospective Studies
D001205:Ascorbic Acid